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Abstract
There is solid evidence that rare variants contribute to complex disease etiology. Next-generation sequencing technologies
make it possible to uncover rare variants within candidate genes, exomes, and genomes. Working in a novel framework, the
kernel-based adaptive cluster (KBAC) was developed to perform powerful gene/locus based rare variant association testing.
The KBAC combines variant classification and association testing in a coherent framework. Covariates can also be
incorporated in the analysis to control for potential confounders including age, sex, and population substructure. To
evaluate the power of KBAC: 1) variant data was simulated using rigorous population genetic models for both Europeans
and Africans, with parameters estimated from sequence data, and 2) phenotypes were generated using models motivated
by complex diseases including breast cancer and Hirschsprung’s disease. It is demonstrated that the KBAC has superior
power compared to other rare variant analysis methods, such as the combined multivariate and collapsing and weight sum
statistic. In the presence of variant misclassification and gene interaction, association testing using KBAC is particularly
advantageous. The KBAC method was also applied to test for associations, using sequence data from the Dallas Heart Study,
between energy metabolism traits and rare variants in ANGPTL 3,4,5 and 6 genes. A number of novel associations were
identified, including the associations of high density lipoprotein and very low density lipoprotein with ANGPTL4. The KBAC
method is implemented in a user-friendly R package.
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Introduction
Currently there is great interest in investigating the etiology of
complex disease due to rare variants [1–6]. Until recently, indirect
mapping of common variants has been the emphasis of complex
trait association studies. It has been demonstrated that common
variants tend to have modest phenotypic effects while rare variants
are likely to have stronger phenotypic effects [7], although not
strong enough to cause familial aggregation [8]. For mapping
complex diseases due to common variants, instead of genotyping
functional variants, tagSNPs are genotyped which act as a proxy
for the underlying causal variants. For rare variant association
studies, indirect mapping is not an optimal approach due to low
correlations (r2) between tagSNPs and rare variants. Instead, direct
mapping should be used, where functional variants are analyzed.
In order to implement direct mapping, variants must first be
identified. Large scale sequencing efforts have begun including the
1000 Genome Project, which will provide a better understanding
of the allelic architecture of the genome and a detailed catalog of
human variants. Next-generation sequencing technologies e.g.
Roche 454, ABI SOLiD, and Illumina HiSeq, have made it
feasible to carry-out rare variant association studies of candidate
regions, exomes and genomes.
Gene interactionsarebelievedtobe involved ina broadspectrum
of complex disease etiologies [9]. Although a number of methods
have been developed to detect gene interactions between common
variants [10–13], their detection has been limited [10]. There is
evidence that rare variant interaction also plays a role in disease
etiology. In direct association mapping of rare variants, one or more
genetic loci are commonly jointly analyzed in order to aggregate
information, for example genes with similar functions or residing in
the same pathway [3,4]. Therefore it is necessary to account for
potentialinteractionsbetween rare variantsindifferentloci [14] and
interactions between common and rare variants [15,16].
Ideally, when carrying out direct mapping, only causal variants
should be tested for associations. When DNA samples are sequenced,
both causal and non-causal variants are uncovered. Bioinformatics
tools [17,18] or filters [1] can be used to predict functionality of
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low sensitivity and specificity [6,19]. Empirical studies have shown
that predictive errors can be as high as 47% and 37% for PolyPhen
and SIFT respectively [6]; therefore, their usefulness in selecting
variants to be included in association analysis is limited. Even when
functionality can be correctly inferred, whether the identified variants
affect the phenotype of interest is still unknown. Two types of
misclassifications of variant causality can frequently arise: 1.) non-
causal variants are included in the analysis: a.) sequencing incorrectly
identifies monomorphic sites as variant sites (false positive SNP
discovery), b.) variants are falsely predicted to be functional or c.)
variants are functional but non-causal; 2.) causal variants are
excluded from the analysis: a.) due to locus heterogeneity, not all
loci containing causal variants are included in the analysis, b.) region
not sequenced, e.g. intronic variants, c.) variants not detected by
sequencing assay (false negative SNP discovery) or d.) causal variants
are falsely predicted to be non-functional.
Driven by the advancement of sequencing technologies and
availability of data, statistical and computational methods are
needed for analyzing sequence data. It has been demonstrated that
methods used to analyze common variants are low powered when
applied to the analysis of rare variants [20,21]. Methods to analyze
rare variants have been proposed [20,21]; although they have
clear advantages over implementing common variant analysis
approaches, more powerful and robust methods need to be
developed to analyze rare variant data, especially in the presence
of variant misclassification or gene interactions.
The Kernel Based Adaptive Cluster (KBAC) was developed to
overcome the problems of detecting rare variant associations in the
presence of misclassification and gene interaction. Under the
KBAC framework, data-based adaptive variant classification and
testing of association are unified. The sample risk of a multi-site
genotype is modeled using a mixture distribution with two
components, where one component represents the distribution of
sample risk of genotype if it is non-causal and the other component
represents distribution of sample risks of causal genotypes. Ideally,
if distributions for causal components were known, classification
could first be performed and only the causal genotypes would be
used in association studies. However, when searching for
genotype-phenotype associations, it is usually unknown which
variants are causal. Instead of performing an unrealistic two-step
procedure, variant classification and association testing are unified
in the KBAC framework. Continuous adaptive weighting which is
implemented in the KBAC is preferable, particularly for low
frequency alleles, than classifying variants and carrying out a
stratified analysis, because increasing classification and shrinking
size of strata can increase both type I and II error. For the KBAC,
adaptive weighting procedure is implemented using the cumula-
tive distribution functions for the multi-site genotype counts.
Distributions of multi-site genotype counts are compared between
cases and controls. Those multi-site genotypes that are enriched in
cases will be up-weighted. Under the null hypothesis, the assigned
weights asymptotically follow a uniform distribution. While under
the alternative hypothesis, disease causal multi-site genotypes tend
to be more frequent in cases than in controls. Therefore they are
more likely to be adaptively up-weighted. The weighted multi-site
genotype frequencies are aggregated and contrasted between cases
and controls. In order to evaluate whether there is an association,
significance of the KBAC can be assessed using either permutation
or Monte Carlo approximation (See Methods and Figure S1).
The performance of the KBAC was compared to the weighted
sum statistic (WSS) [21] the combined multivariate and collapsing
(CMC) method [20], and the comparison of rare variants found
exclusively in cases to those found only in controls (RVE) [3] using
simulated data sets. Forward time simulation [22] assuming
infinite-site Wright-Fisher model was used to generate population
genetic data. Demographic change and purifying selection were
both incorporated in the simulation, using parameters estimated
from re-sequencing datasets from studies of African Americans
(AA) and European Americans (EA) [23]. In addition to forward
time simulation, population genetic data was also generated
according to estimated site frequency spectrums (SFS) in AA and
EA from the Dallas Heart Study (DHS) re-sequencing data of the
ANGPTL3, 4, 5, and 6 genes.
For the simulated population data phenotypes were generated
separately and motivated by epidemiological disease studies. Two
types of main effects phenotypic model are considered: 1.) constant
genetic effects for each causal variant and 2.) genetic effects
inversely correlated with minor allele frequencies (MAF) of causal
genetic variants. In order to evaluate the impact of variant
misclassification, a variety of scenarios were examined where 1.)
different proportions of non-causal variants were included in the
analysis and 2.) different proportions of causal variants were
excluded from the analysis.
Two disease models of gene interactions were also evaluated.
The example of with-in gene interaction was motivated by
Hirschsprung’s disease [15,16], where an interaction between a
common polymorphism in the promoter region and multiple rare
non-synonymous (NS) mutations in exonic regions of the RET
gene is hypothesized [15,16]. The example of between gene
interaction is based on the observation that rare variants within the
CHEK2 gene increase risk of breast cancer in the absence of
BRCA1 and BRCA2 mutations, but because of a shared pathway,
the same CHEK2 variants in the presence of high risk BRCA
variants do not further increase risk [14,24,25].
Under each of the above scenarios, phenotype-genotype
association testing is performed for rare NS variants. It is
demonstrated that the KBAC has a clear advantage in power
and robustness over other existing methods and this benefit is
especially strong, when rare variant data is analyzed where there is
either variant misclassification or gene interactions.
In order to further illustrate applications of the KBAC and
other statistical methods, i.e., WSS, CMC, and RVE to carry-out
Author Summary
It has been demonstrated that both rare and common
variants are involved in complex disease etiology. Until
recently it was only possible to perform large scale analysis
of common variants. With the development of next-
generation sequencing technologies, detection and map-
ping of rare variants have been made possible. However,
methods used to analyze common variants are not
powerful for the analysis of rare variants. To address the
problems of rare variant analysis working in a novel
framework, the kernel-based adaptive cluster (KBAC)
method was developed to perform gene/locus based
analysis. The KBAC combines variant classification and
association testing in a coherent framework. Through
simulations motivated by population genetic and disease
data, it is demonstrated that the KBAC has superior power
to other rare variant analysis methods, especially in the
presence of variant misclassification and gene interaction.
Using data from the Dallas Heart Study, the KBAC method
was applied to test for associations between energy
metabolism traits and rare variants in ANGPTL 3,4,5 and 6
genes. A number of novel associations were identified. The
KBAC method is implemented in a user-friendly R package.
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ANGPTL 3, 4, 5 and 6 genes obtained from sequence data were
analyzed. In addition to identifying the originally reported
association between triglyceride levels and ANGPTL 4, KBAC
identified associations for a.) body mass index and ANGPTL 5, b.)
diastolic blood pressure with ANGPTL 6, c.) high density
lipoprotein with ANGPTL 4, d.) triglyceride levels with ANGPTL
3 e.) very low density lipoprotein with ANGPTL 3 and ANGPTL 4.
Results
The results presented focus on simulations using simulated SFS
from AA sequence data. Similar results are found for simulations
using simulated SFS for EA and estimated SFS for AA and EA
(Text S1 and Figures S2, S3, S4, S5, S6, S7, S8.). Although the
power varies dependent on the underlying model used to generate
the data, in all cases the KBAC is the most powerful method
followed by the WSS, CMC and then the RVE.
Rare Variant Frequency Distributions in Generated
Case-Control Samples
Rare NS variants carrier information is summarized (Table 1)
for replicates used in power comparisons in the presence of
misclassifications. Under the phenotypic model with variable
genetic effects, when all variants (both non-causal and causal
variants) were analyzed, 5.5% of cases and 3.4% of controls are
carriers, with carrier frequency in cases 61% higher than in
controls. When only causal variants are included, the fractions of
carriers in cases and in controls are 3.8% and 1.7% respectively.
The case rare variant frequency is approximately 2.3 times of the
controls frequency, which implicates that average ORs of
uncovered rare variants lie between 2 to 3. For the phenotypic
model with fixed genetic effects, the results are similar. The carrier
frequency observed in cases is around 2.5 times the frequency in
controls. Compared to the model with fixed effects, lower
frequency rare causal variants have larger ORs for variable effects
model. The probability that these low frequency rare variants are
uncovered in a case-control sample is higher. Therefore, in all
scenarios examined, more rare variants sites are uncovered for the
model with variable effects. When all the variants are included,
11% more rare NS variants sites are uncovered for the model with
variable effects. The number of rare variants sites that are
exclusive to cases or controls is also higher under the variable
effect model. For example, when 100% of the variant sites are
included in the analysis, 47.4% and 41.1% of the sites are found
exclusively in either cases or controls for the variable and the fixed
effects model, respectively. For both models, within a single gene,
very few cases and controls carry more than one rare variant.
Table 1. Rare variant summary statistics.
Scenario
Rare Variant Carrier
Frequencies in Cases/
Controls
Mean Number
of Rare Variant
Sites
Mean number of Rare Variant
Sites Observed Exclusively in
Cases/Controls
Proportions of Rare Variant
Carriers with More than One
Rare Variant in Case/Controls
Phenotypic Model with Variable Genetic Effects Inversely Correlated with MAFs
Percentage of Causal
Variants Excluded
20% 0.033/0.014 5.791 2.978 0.013/0.006
40% 0.025/0.011 4.396 2.285 0.009/0.004
60% 0.017/0.008 3.048 1.556 0.006/0.003
Percentage of Non-
causal Variants Included
0% 0.038/0.017 6.942 3.609 0.016/0.006
20% 0.041/0.02 7.614 3.859 0.018/0.008
40% 0.044/0.023 8.501 4.274 0.019/0.009
60% 0.048/0.027 9.535 4.645 0.021/0.012
80% 0.051/0.03 10.539 5.044 0.022/0.014
100% 0.055/0.034 11.665 5.53 0.025/0.016
Phenotypic Model with Fixed Genetic Effects Unrelated to MAFs
Percentage of Causal
Variants Excluded
20% 0.034/0.014 4.455 1.797 0.014/0.005
40% 0.027/0.011 3.449 1.39 0.01/0.004
60% 0.019/0.008 2.36 0.956 0.006/0.003
Percentage of Non-
causal Variants Included
0% 0.041/0.017 5.325 2.158 0.017/0.007
20% 0.043/0.019 5.996 2.439 0.018/0.008
40% 0.047/0.023 7.058 2.875 0.02/0.01
60% 0.05/0.027 8.007 3.259 0.022/0.013
80% 0.054/0.03 8.931 3.565 0.024/0.013
100% 0.057/0.034 10.047 4.132 0.026/0.015
The summary statistics are displayed for the generated replicates under main effects model with fixed and variable genetic effects using simulated SFS from AA
population. Scenarios with different proportions of causal variants excluded and scenarios with different proportions of non-causal variants included were considered.
The table displays for a given sample, the information on a) the average proportion of rare NS variant carriers among cases and controls; b) the mean number of rare NS
variant sites; c) the mean number of rare NS variant sites that are exclusive to cases or controls; d) the average proportion of case and control rare NS variant carriers
with more than one rare variant. For each scenario, a sample size of 1,000 cases and 1,000 controls were used. 2,000 replicates were generated for each scenario.
doi:10.1371/journal.pgen.1001156.t001
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patterns of NS variants sites and carrier frequencies are observed.
When 100% of the rare variants are causal, 5.5% of the cases and
3.2% of the controls are carriers on average for a case-control
sample. Due to interaction, frequency differences between cases
and controls are mitigated. In the between gene interaction
model (Table 2), higher case carrier frequency and more rare
variants sites are observed for the high risk gene than for the low
risk gene. The proportions of rare variants carriers for the two
genes combined can be high, e.g. when 100% of the variants are
causal, up to 12% of the cases can be rare variant carriers. Rare
variants distributions can be found in the (Text S1) for main
effects models (Table S1) and within and between gene
interactions models (Table S2) using simulated SFS for EA, and
for main effects models using estimated SFS for AA (Table S3)
and EA (Table S4) with re-sequencing data from ANGPTL3, 4, 5,
and 6 genes.
Evaluation of Type I Error
When permutation was used to evaluate significance for the
KBAC, type I error was well controlled, because p-values were
obtained empirically. Additionally, in order to ensure that the type
I error for RVE is well controlled permutation is also used to
obtain empirical p-values. For the WSS [21], CMC [20] method,
it was previously demonstrated that for the analysis of rare
variants, their type I errors are well controlled [20]. For moderate
sample sizes e.g. 400 cases/400 controls, the distributions of
p-values for the Monte Carlo approximation are very close to
those obtained using permutations and theoretical expectations
(Figure 1) and additionally type I error is well controlled.
Power Comparison
Main effects model without misclassification. For main
effects model with fixed genetic effects and no misclassification
(Figure 2), the power 1{b ðÞ for KBAC, WSS CMC and RVE are
respectively given by 82.5%, 77.7%, 73.9% and 14.8%. The
power for RVE is much lower than the power for the other three
methods. For the main effects model with variable genetic effects
(Figure 3), the power for the four methods is given by 83.1%,
78.8%, 74.2% and 44.8%. The power of the RVE improves for
the variable genetic effects model compared to the fixed genetics
effect model; while the power for the other methods remains
relatively unchanged. KBAC is consistently more powerful than
WSS, CMC and RVE, e.g. for fixed effect model, KBAC is 6.1%
more powerful than WSS, 11.6% more powerful than CMC, and
457.4% more powerful than RVE.
Impact of misclassification. Under both models (Figure 2,
Figure 3), the power of all methods is negatively impacted by
exclusions of causal variants and inclusions of non-causal
variants at a varying degree. When non-causal variants are
included in the analysis, KBAC is consistently more powerful
and more robust than the other three methods. For example,
when 100% of the non-causal variants are included, under the
variable effects model, KBAC 1{bKBAC~69:9% ðÞ is 19.3%
more powerful than WSS 1{bWSS~58:6% ðÞ , 27.6% more
powerful than CMC 1{bCMC~54:8% ðÞ , and 91.0% more
powerful than RVE 1{bRVE~36:6% ðÞ . When compared under
the fixed effects model, the advantage of KBAC 1{bKBAC ð
~71:2%Þ over WSS 1{bWSS~61:1% ðÞ ,C M C 1{bCMC~ ð
58:2%Þ and RVE 1{bRVE~13:9% ðÞ remains largely unchanged.
For the scenarios where causal variants are missing, the relative
Table 2. Rare variant summary statistics.
Scenario
Rare Variant Carrier
Frequencies in Cases/
Controls
Mean Number
of Rare Variant
Sites
Mean number of Rare Variant
Sites Observed Exclusively in
Cases/Controls
Proportions of Rare Variant
Carriers with More than One
Rare Variant in Case/Controls
Between Gene Interaction Model
Percentage of
Causal Variants:
25% Gene 1 0.049/0.035 7.348 3.612 0.022/0.015
Gene 2 0.038/0.035 7.023 3.39 0.018/0.016
50% Gene 1 0.065/0.035 7.699 3.749 0.029/0.015
Gene 2 0.042/0.034 7.174 3.475 0.019/0.016
75% Gene 1 0.079/0.034 8.146 4.024 0.035/0.015
Gene 2 0.046/0.034 7.259 3.509 0.021/0.015
100% Gene 1 0.096/0.034 8.622 4.276 0.043/0.015
Gene 2 0.049/0.035 7.432 3.553 0.023/0.016
Within Gene Interaction Model
Percentage of
Causal Variants
25% 0.037/0.032 9.109 2.999 0.016/0.014
50% 0.043/0.032 9.295 3.026 0.02/0.014
75% 0.048/0.031 9.352 3.003 0.022/0.014
100% 0.055/0.032 9.627 3.042 0.028/0.014
The summary statistics are displayed for the generated replicates under within gene interaction model and between gene interaction model using simulated SFS from
AA population. Scenarios with different proportions of causal variants were considered. The table displays for a given sample, the information on a) the average
proportion of rare NS variant carriers among cases and controls; b) the mean number of rare NS variant sites; c) the mean number of rare NS variant sites that are
exclusive to cases or controls; d) the average proportion of case and control rare NS variant carriers with more than one rare variant. For within gene interaction model,
a sample size of 1,000 cases and 1,000 controls were used, and for the between gene interaction model, a sample size of 300 cases and 300 controls were used. 2,000
replicates were generated for each scenario.
doi:10.1371/journal.pgen.1001156.t002
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KBAC.WSS.CMC.RVE. For the variable effects model, the
power advantage of WSS over CMC is greater than the advantage
observed for the fixed effects model. For example, when 60% of the
causal variants are excluded from the analysis, under the fixed effects
model, the power for WSS drops 40.1% and the power of CMC
drops 45.1%, while under the variable effects model, the power
decreases for WSS and CMC are respectively 39.1%, 47.8%. The
KBAC is more robust than the other methods: the power decreases
under the fixed and variable effects models are respectively 34.1%
and 35.6%, which are smaller than the decreases in power for WSS
and CMC. Exclusion of causal variants from the analysis is more
detrimental to power than inclusion of non-causal variants. Power
comparisons with simulated SFS for EA can be found in (Figure S2)
for fixed effects model and in (Figure S3) for variable effects model.
Additionally, power comparisons with estimated SFS for AA are
Figure 1. Quantile-Quantile (QQ) plot of p-values obtained from Monte Carlo approximation (left panel), permutation (right panel),
and theoretical expectations. P-values were estimated using 10,000 iterations and 10,000 permutations for Monte Carlo approximation and
permutation, respectively. Four sample sizes were investigated: 200 cases/200 controls; 300 cases/300 controls, 400 cases/400 controls, and 500
cases/500 controls. A total of 3,000 replicates were used to generate the QQ plot for each sample size.
doi:10.1371/journal.pgen.1001156.g001
Figure 2. Impact of misclassifications under main effects model with fixed genetic effects using simulated SFS for AA. Each causal
rare variant has an OR=3.0. Power comparisons were made for the KBAC, WSS, CMC, and RVE when 0%,60% of causal rare variants are excluded
from the analysis (left panel) and when 0%,100% of non-causal rare variants are included (right panel). A sample size of 1000 cases and 1000
controls was used for each scenario. P-values were empirically estimated using 5,000 permutations and power was evaluated for a significance level
of a~0:05 using 2,000 replicates for each scenario.
doi:10.1371/journal.pgen.1001156.g002
A Novel Adaptive Method for Rare Variant Analysis
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models and that with estimated SFS for EA are displayed in (Figure
S6) for fixed and in (Figure S7) for variable genetic effects models.
Within gene interaction model. Under the within gene
interaction model, KBAC is consistently the most powerful
method for all scenarios with different proportions of causal
variants (Figure 4). The advantage of KBAC in the presence of
interactions is apparent and its advantage over other methods
becomes greater with increasing proportion of non-causal variants.
For example, when all variants are causal, the power of KBAC is
8.4% higher than WSS, which is the second most powerful
method. But when only 50% of all variants are causal, KBAC is
Figure 3. Impact of misclassifications under main effects model with variable genetic effects using simulated SFS for AA. The disease
odds for causal variants are inversely correlated with their MAFs and within the range of 2,20. Power comparisons were made for the KBAC, WSS,
CMC, and RVE when 0%,60% of causal rare variants are excluded from the analysis (left panel) and when 0%,100% of non-causal rare variants are
included (right panel). A sample size of 1000 cases and 1000 controls was used for each scenario. P-values were empirically estimated using 5,000
permutations and power was evaluated for a significance level of a~0:05 using 2,000 replicates for each scenario.
doi:10.1371/journal.pgen.1001156.g003
Figure 4. Power comparisons for within gene (left panel) and between gene interaction model (right panel) with simulated SFS for
AA. Power was evaluated for the KBAC, WSS, CMC and RVE. A sample size of 1000 cases and 1000 controls were used for the within interaction
model, and a sample size of 300 cases and 300 controls were used for the between gene interaction model. Scenarios with different proportions of
causal variants were considered. P-values were empirically estimated using 5,000 permutations and power was evaluated for a significance level of
a~0:05 using 2,000 replicates.
doi:10.1371/journal.pgen.1001156.g004
A Novel Adaptive Method for Rare Variant Analysis
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methods for all scenarios compared.
Between gene interaction model. In the between gene
interaction model, power comparisons between the four methods
remain similar (Figure 4). KBAC is consistently the most powerful
method and is robust against inclusion of non-causal rare variant sites.
Comparing the scenario where all variants are causal with the scenario
where only 50% of the variants are causal, the power for KBAC drops
36.3%, while the power for WSS drops 48.2%. Power comparisons
for within and between gene interaction models using simulated SFS
b a s e do ns e q u e n c ed a t af r o mE Ac a nb ef o u n di n( F i g u r eS 8 ) .
ANGPTL Variants and Energy Metabolism in Humans
In order to further illustrate the application of KBAC and other
rare variant analysis methods (i.e. WSS, CMC and RVE), rare
variants in the ANGTPL 3,4,5 and 6 genes were analyzed to
determine whether they are associated with energy metabolism
traits (Table 3). As in the original DHS study [26], the association
of rare variants in the ANGPTL3,4,5 and 6 genes with triglyceride
(TG), low density lipoprotein (LDL), very low density lipoprotein
(VLDL), high density lipoprotein (HDL), cholesterol, glucose,
body mass index (BMI), systolic (SysBP) and diastolic blood
pressure (DiasBP) were investigated. In the original DHS study,
NS variants were analyzed using RVE, and significant associations
were found between ANGPTL3, ANGPTL 4 and TG as well as
between ANGPTL 6 and cholesterol [5,6]. In this article NS
variants, most of which are very rare [5,6], were analyzed.
Individuals with confounding factors (lipid lowering drugs,
diabetes mellitus and heavy alcohol use) were removed for all
analyses. Multiple associations were identified with KBAC but not
with other approaches, i.e. the novel associations between
ANGPTL 6 and DiaBP pKBAC~0:045,pWSS~0:084,pCMC~ ð
0:088,pRVE~0:405Þ, as well as between ANGPTL 3 and TG
levels pKBAC~0:015,pWSS~0:053,pCMC~0:058,pRVE~0:312 ðÞ .
Additionally multiple novel associations were observed for analyses
carried out with KBAC, WSS and CMC: 1.) ANGPTL4 and VLDL
pKBAC~0:001,pWSS~0:006,pCMC~0:010,pRVE~0:141 ðÞ ; 2.)
ANGPTL5 and BMI pKBAC~0:001,pWSS~0:003,pCMC~0:006, ð
pRVE~0:263Þ; 3.) ANGPTL4 and HDL pKBAC~0:021,pWSS~ ð
0:041,pCMC~0:045,pRVE~0:681Þ and 4.) the previously reported
association between ANGPTL4 and TG levels pKBAC~ ð
0:004,pWSS~0:005,pCMC~0:006,pRVE~0:087Þ. It should be
noted that HDL and TG levels are negatively correlated (20.42)
and individuals with HDL levels in the lower quartile had an excess
of rare variants in ANGPTL4 compared to those individuals with
HDL levels in the upper quartile, while those individuals with TG
levels in the upper quartile had an excess of rare variants in
ANGPTL4 compared to those with TG levels in the lower quartile.
Theassociationdetected byKBAC between ANGPTL4 andVLDL
and between ANGPTL5 and BMI remains significant after
correcting for multiple testing. RVE, on the other hand, detected
associationsbetweenANGPTL5,6 and glucose whiletheotherthree
methods did not. We further investigated this association by
applying a more stringent MAF cutoff 0.1% for the NS variants
analyzed in ANGPTL 5 and 6. Using this new criterion both
associations were detected by all methods (for ANGPTL 5,
pKBAC~0:001,pWSS~0:006,pCMC~0:011,pRVE~0:011 ðÞ and for
ANGPTL 6, pKBAC~0:002,pWSS~0:008,pCMC~0:012,pRVE~ ð
0:012Þ).
Discussion
The KBAC method developed for association mapping of rare
variants combines genotype classification and hypothesis testing in
a coherent framework. The risk of each multi-site genotype is
modeled as a mixture distribution with two components, among
which only the component representing a non-causal genotype is
known and is used in the adaptive weighting. Each multi-site
genotype is continuously weighted using the non-causal compo-
nent. The power of the KBAC as well as the other methods
investigated can be affected by inclusion of non-causal mutations
or exclusion of causal variants in the sample, to a varying degree.
When non-causal variants are included in the analysis, the
difference in rare variant carrier frequencies observed between
cases and controls is mitigated. On the other hand, when causal
variants are excluded from the association analysis, the marginal
effect size of existing variants can vary considerably depending on
whether missing causal variants exist on the same multi-site
genotype. As a result, treating each variant (or multi-site genotype)
interchangeably will incur loss of power, the severity of which will
depend on the proportion of misclassified variants in the data. The
performance of the KBAC is superior to the other approaches that
were examined.
Bioinformatics tools [17,18] and filters [1] can be used to
determine which rare variants are potentially functional and should
beincluded inthe association analysis [1].Theirpredictive accuracy,
which can be low, is dependent on the amount of information
available for the gene understudy. If bioinformatics tools are used to
predict variant functionality and determine which variants should be
included in the analysis it is best to loosen stringency, because the
exclusion of causal variants is more detrimental to power than
inclusion of non-causal variants. Whether or not bioinformatics tools
are used as a screening tool, misclassification will occur therefore the
robustness of KBAC to misclassification is particularly beneficial.
Additionally in order to avoid potentially erroneous exclusion of
causal variants due to locus heterogeneity, joint analysis of multiple
putative genetic loci that carry similar functions or reside in the same
pathway can be valuable.
It is of great interest to evaluate gene6gene interactions in the
study of complex diseases. The KBAC analyzes multi-site
genotypes (or multi-locus genotype), which can be beneficial in
detecting gene interactions [11]. This property is especially
important when multiple genetic loci are jointly analyzed in order
to aggregate rare variants. Interactions are more likely to occur
between genes involved in the same pathways. In addition, it has
been hypothesized that functions of rare variants can be
modulated by common variants [8]. Since the KBAC uses
adaptive weighting instead of a fixed model, unknown patterns
of gene interaction can be automatically integrated into the
analysis. Through models motivated by Hirschsprung’s disease
and breast cancer, it is shown that in the presence of interactions
the KBAC outperforms other approaches. An additional advan-
tage of the KBAC is that kernel weights computed for adaptive
weighting provide a measure with which the relative risk of each
multi-site genotype can be assessed, for further replication studies.
The RVE method which compares the occurrence of variants
which are exclusively observed in cases to those which are only
observed in controls has the lowest power among all tests
evaluated. The RVE method possesses undesired statistical
properties by excluding those variants which are observed in both
cases and controls. For all variants that are not fully penetrant,
when sample size is large, they tend to appear in both case and
control samples and would thus be excluded from the analysis
using RVE. As a result, the RVE method is not asymptotically
consistent; with increasing sample size power may be even lower
than for smaller sample sizes [27].
Forward time simulations of locus genetic data incorporated
both population demographic change and purifying selection.
A Novel Adaptive Method for Rare Variant Analysis
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(especially NS variants). Only NS variants were analyzed for
comparing different methods, as it has been suggested that using
NS variants will concentrate variations on functionally significant
class of alleles, and increase signal to noise ratio [27]. There have
been a number of studies on complex diseases which identified
associations with NS variants [3,5,6]. When synonymous muta-
tions are also considered in the analyses, higher proportions of
non-causal variants may be introduced, so the adaptive property
and the robustness of KBAC will be more advantageous.
Whether or not phenotypic effects of causal rare variants are
inversely correlated with their MAF is unknown. Deleterious
functional variants tend to have low frequencies [28], but the
functional effect of a deleterious mutation may not be associated
with the disease. On the other hand, for mutations involved in
complex traits, they may not be at selective disadvantage due to
Table 3. Association analyses of the ANGPTL 3,4,5 and 6 gene variants with human energy metabolism phenotypes.
Phenotype Gene Name KBAC WSS CMC RVE
Numbers of Carriers
of Rare Variants
Observed in Upper/
Lower Quartiles
Number of Carriers of Rare
Variants Observed
Exclusively in either the
Upper or Lower Quartiles
BMI ANGPTL3 0.556 0.832 0.915 0.746 47/48 8/6
ANGPTL4 0.999 0.331 0.412 0.104 62/71 2/7
ANGPTL5 0.001* 0.003** 0.006** 0.263 83/51 5/1
ANGPTL6 0.128 0.189 0.217 0.410 40/29 9/5
DiasBP ANGPTL3 0.237 0.805 0.759 0.950 53/49 6/6
ANGPTL4 0.784 0.437 0.445 0.086 56/63 3/9
ANGPTL5 0.432 0.590 0.652 0.636 71/65 3/4
ANGPTL6 0.045* 0.084 0.088 0.405 49/33 12/7
SysBP ANGPTL3 0.455 0.965 1.000 0.919 49/48 7/6
ANGPTL4 0.409 0.835 0.789 0.935 71/67 6/6
ANGPTL5 0.106 0.498 0.602 0.053 77/71 10/2
ANGPTL6 0.473 0.349 0.346 0.510 34/42 11/7
Cholesterol ANGPTL3 0.950 0.299 0.326 0.906 40/49 7/7
ANGPTL4 0.260 0.503 0.515 0.123 68/59 4/9
ANGPTL5 0.353 0.697 0.783 0.778 68/63 8/7
ANGPTL6 0.348 0.573 0.628 0.052 38/33 10/2
LDL ANGPTL3 0.792 0.894 1.000 0.855 46/46 8/7
ANGPTL4 0.508 0.695 0.709 0.064 66/60 4/11
ANGPTL5 0.544 0.908 0.860 0.278 73/70 1/4
ANGPTL6 0.307 0.745 0.813 0.388 39/36 9/5
HDL ANGPTL3 0.834 0.992 1.000 0.237 50/51 2/7
ANGPTL4 0.021* 0.041* 0.045* 0.681 84/62 7/6
ANGPTL5 0.077 0.115 0.123 0.170 85/67 5/1
ANGPTL6 0.143 0.211 0.239 0.513 43/33 6/9
TG ANGPTL3 0.015* 0.053 0.058 0.312 34/52 6/11
ANGPTL4 0.004** 0.005** 0.006** 0.087 46/76 2/8
ANGPTL5 0.212 0.678 0.852 0.165 62/64 1/5
ANGPTL6 0.683 0.664 0.709 0.057 35/32 15/6
VLDL ANGPTL3 0.028* 0.047* 0.061 0.352 35/53 7/12
ANGPTL4 0.001** 0.006** 0.010* 0.141 49/80 3/9
ANGPTL5 0.265 0.941 1.000 0.263 67/68 1/5
ANGPTL6 0.706 0.756 0.806 0.140 35/34 12/6
Glucose ANGPTL3 0.485 0.589 0.612 0.690 49/55 5/7
ANGPTL4 0.872 0.549 0.659 0.706 75/67 6/7
ANGPTL5 0.407 0.896 0.862 0.021* 76/72 1/9
ANGPTL6 0.196 0.198 0.239 0.026* 44/32 14/3
Nine phenotypes were analyzed: triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), total cholesterol,
glucose, body mass index (BMI), and systolic (SysBP) and diastolic (DiasBP) blood pressure. Analyses were carried-out including only NS variants. The KBAC, WSS, and
CMC were used to analyze each trait and nominally significant p-values are indicated with an asterisk. The p values for KBAC, WSS and RVE were obtained empirically
using 10,000 permutations, while the p-value for CMC was analytically calculated.
doi:10.1371/journal.pgen.1001156.t003
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reductions in reproductive fitness. For both types of models, the
advantage of KBAC is apparent. WSS and RVE perform better
under the variable effects models, when only causal variants are
present. This is because high risk causal variants are assigned
higher weights. However, as low frequency non-causal variants
also receive larger weights that negatively affect power, there are
no measurable improvements of WSS compared to the model with
fixed genetic effects. On the other hand, due to the adaptive
nature of KBAC, the method performs consistently the best under
both classes of models.
The KBAC test statistic does not have a closed form
distribution; therefore it is necessary to evaluate significance either
through permutation or using Monte Carlo approximation. For
small sample sizes i.e. ,#400 cases and 400 controls, permutation
is recommended, because it can be more reliable than Monte
Carlo approximation. For larger sample sizes, Monte Carlo
approximation not only controls type I error, but also the estimates
of power do not differ from those obtained using permutations
(data not shown). Permutation can be computationally intensive
for large samples and/or genome-wide data where a large number
of genetic regions are analyzed; therefore Monte Carlo approx-
imation can be particularly advantageous to evaluate significance
due to its computational efficiency.
A well known problem of genetic association studies is spurious
findings due to population substructure and/or population
admixture. For rare variant association analysis this problem can
occur when study subjects are sampled from different populations
and the distribution of non-causal variant sites and/or aggregate
frequencies of non-causal variants differ between the sampled
populations. To control for population stratifications, KBAC can
be coupled with principal components analysis (PCA) [29]
approach and eigenvector(s) can be included as covariates in the
analysis (see Methods: Controlling for Confounders). PCA
approach has been shown to be a powerful tool to accurately
infer geographical locations [30,31]. In addition, KBAC can also
be used with clustering/matching based methods, such as
structured association [32,33] to control for population stratifica-
tion.
The application of KBAC as well as WSS, CMC and RVE were
further illustrated by the analyses of genes in ANGPTL family. In
the analyses, all individuals with potentially confounding factors
i.e. diabetics, alcoholics, and individuals treated with lipid lowering
drug were excluded. In the original studies individuals were
excluded based upon both their quantitative trait values and the
confounding factors. For example, only individuals treated with
lipids lowering drugs in the lower quartile of TGs were removed,
but those in the upper quartile were included in the analysis. We
believe excluding individuals based upon their quantitative trait
values should not be done instead all individuals meeting the
exclusion criteria should be removed from the analysis. KBAC
performs consistently well, and identifies the most phenotype-
genotype associations among all the approaches compared. The
effects of mutant ANGPTL genes on lipoprotein lipase (LPL) have
been studied through in vitro functional studies and in vivo mice
studies. LPL has been known to affect glucose metabolism [34],
cholesterol level [34–37], and blood pressure [38]. This biological
evidence strengthens the support of the identified associations.
Additionally, the association between variants in ANGPTL4 gene
and triglyceride levels were successfully replicated using an
independent dataset [5,6].
Although the examples given are for the analysis of single
regions and interaction between two regions, the KBAC can also
be used to analyze entire exomes (or genomes). In order to control
for family-wise error rate (FWER), it is sufficient to use a
Bonferroni correction, since there will be little or no linkage
disequilibrium between rare variants in different genes. It is thus
not necessary to control the FWER using permutations. If exome
sequencing is carried out and analysis is implemented gene by
gene, given that human genome contains ,20,000 genes, a
significance level a~0:05=20,000~2:5|10{6 can be applied.
The correction necessary for gene based association mapping of
rare variants is less than the threshold currently used for genome-
wide association studies [39] which is usually a~5|10{8.
The KBAC is a powerful tool to detect main association effects and
gene interactions in large sequence data sets of candidate genes,
exomesandin thefutureentiregenomes.TheKBACisimplemented
in a user friendly R package and is available from the authors.
Methods
Sample Risk
Total sample size is denoted as N, among which there are NA
affected (A) and NU~N{NA unaffected (U). It is assumed that
there are M sites within the candidate region where rare variants
are observed. The rare variant multi-site genotype for each
‘‘individual’’ is contained in a vector G~ g1,g2,   ,gM ðÞ , with the
jth entry being the number of rare variants observed at jth site, i.e.
gj has value 2 if the site is homozygous for the rare allele, 1 if the
site is heterozygous, 0 if the site is homozygous wild-type for the
common major alleles. It is further assumed that kz1 distinct
multi-site genotype vectors, i.e G0,G1,G2,:::Gk are observed,
where G1,G2,:::Gk are multi-site genotypes with at least one rare
variant and G0 represents the wild-type genotype without any rare
variants (i.e. a vector of all 0’s). The sample risk for multi-site
genotype Gi is defined as
Ri~
NA
i
Ni
,
which is a consistent estimator of the ratio
NA|P½GiDA 
NA|P½GiDA z N{NA ðÞ |P½GiDU 
:
The ratio increases with disease penetrance of Gi and provides a
sample based measure of the relative risk.
The sample risk Ri for multi-site genotype Gi is modeled using a
mixture distribution with two components, Ri *
D pik0
i Ri ðÞ z
1{pi ðÞ kA
i Ri ðÞ . The component k0
i Ri ðÞ represents the distribution
of the sample risk when multi-site genotype Gi is non-causal and is
known, while kA
i Ri ðÞ represents the unknown distribution of
sample risk when Gi is causal. If the null hypothesis holds, all
genotypes are non-causal, therefore, pi~1. Under the alternative
hypothesis, each genotype can be either causal or non-causal and
the probabilities pi in the probabilistic mixtures are unknown.
If the mixture distribution under the alternative were known,
then each genotype could be classified and only the causal
genotypes would be used in the analysis. However, in disease gene
mapping, the causality of variants is unknown. Instead of trying to
‘estimate’ pi and kA
i which are unknown, each multi-site genotype
is adaptively weighted using only the known component, k0
i . ðÞ .
Each k0
i . ðÞis called a kernel. The term kernel is borrowed from
density estimation, where the density being estimated is spanned
by a linear combination of kernel functions. The weight each rare
genotype carries is given by the area under the curve which can be
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wi~
ð^ R Ri
0
k0
i (r)dr~K0
i ^ R Ri
  
,
where ^ R Ri is the estimated sample risk for multi-site genotype Gi.
Thereby, under the null hypothesis, the weights are uniformly
distributed and under the alternative, greater weights can be
placed on the multi-site genotypes that are enriched in cases. The
genotypes with high sample risks will be given higher weights
which can potentially separate causal from non-causal genotypes.
Instead of classifying genotypes in a rigid manner with unknown
likelihoods, this method weighs each genotype in a continuous
fashion using only the known component k0
i . ðÞfrom the mixture
density. The adaptive weighting procedure in the KBAC attains a
good balance between classification accuracy and the number of
parameters which are estimated.
Choice of Kernels
Three types of kernels can be used to assign weights to each rare
genotype; they are asymptotically equivalent. For small to
moderate sample sizes, binomial and hyper-geometric likelihoods
tend to work best, while for large sample sizes the asymptotic
normal kernel is computationally efficient. All examples shown in
this article were carried out using the hyper-geometric kernel.
Hyper-geometric kernel. Under the null hypothesis of no
disease/gene associations, conditioning on the genotype counts
Ni~ni fg iƒk and the count of cases and controls fNA~nAg, the
number of diseased ‘‘individuals’’ having multi-site genotype Gi
i.e. nA
i ~niri follows a hyper-geometric distribution with kernel
function given by
k0
i ri ðÞ ~P½Ri~riDfNi~nigiƒk,NA~nA ~
ni
niri
  
n{ni
nA{niri
  
n
nA
  
As this distribution is discrete, the integral is replaced by
summations, i.e.
K0
i ^ R Ri
  
~
X
ri[
0
ni
,   ^ R Ri
   k0
i ri ðÞ
Marginal binomial kernel. Under the null hypothesis of no
disease/gene association, conditioning on the genotype counts
Ni~ni fg iƒk, marginally, the number of disease ‘‘individuals’’ with
genotype Gi, nA
i ~niri satisfies a binomial distribution,
nA
i *Binom ni,
nA
n
  
. Thus,
k0
i ri ðÞ ~P½Ri~ri ~
ni
niri
  
nA
n
   niri
1{
nA
n
   ni 1{ri ðÞ
:
The weight as above is obtained through summations, i.e.
K0
i ^ R Ri
  
~
X
ri[
0
ni
,   ^ R Ri
   k0
i ri ðÞ :
Asymptotic normal kernel. Under the null distribution, the
sample risk for genotype Gi is asymptotically normal, i.e.
ﬃﬃﬃﬃ
ni
p
Ri{
nA
n
  
{  ?
D
N 0,
nA
n
1{
nA
n
     
so the kernel is given by k0
i ri ðÞ ~
ﬃﬃﬃﬃ
ni
p
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
nA
n
1{
nA
n
   s w
ﬃﬃﬃﬃ
ni
p
ri{
nA
n
  
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
nA
n
1{
nA
n
   s
0
B B B B @
1
C C C C A
, where w . ðÞ is the probability density
function for a standard normal random variable. The weight for
genotype Gi is given by the integral
K0
i ^ R Ri
  
~
ð^ R Ri
0
k0
i ri ðÞ dri:
Test Statistics
Each ‘‘individual’’ with multi-site genotype Gi in the sample will
be assigned weight wi. The weight is given by the kernel functions
depending on the estimated sample risk ^ R Ri i.e. wi~K0
i (^ R Ri). The
weights assigned to rare genotypes are aggregated and contrasted
between cases and controls.
The KBAC statistic is defined as KBAC~
P k
i~1
NA
i
 
NA{
 
 
NU
i
 
NUÞK0
i ^ R Ri
  
Þ
2, which compares the difference of weighted
multi-site genotype frequencies between cases and controls.
When a one sided alternative hypothesis is tested, e.g. the
enrichment of causal variants in cases, a corresponding one sided
version of KBAC can be used, i.e. KBAC1~
P k
i~1
NA
i
 
NA{
 
NU
i
 
NUÞK0
i ^ R Ri
  
. In this article, all power comparisons were
based upon two sided tests for each method.
Standard permutation procedure is used to obtain empirical
p-values for small sample sizes and for large sample sizes
significance can be obtained through the Monte Carlo approxi-
mation. A graphical illustration of the KBAC statistic can be found
in (Figure S9).
Controlling for Confounders
In order to control for sample heterogeneities such as
population stratification/admixture, it is desirable to be able to
incorporate covariates in the association analysis. The kernel
weights computed for the KBAC statistic can be used with logistic
regression. For an individual j with multi-site genotype Gi,w e
define a variable for the kernel weight, i.e. Xj~wi. The logistic
regression model for association testing has the form
log
PY j~1DXj,Zjl
  
1{PY j~1DXj,Zjl
  
 !
~b0zb1Xjz
X
l alZjl
where Zjl
  
j,l are the covariates such as age, sex or eigenvectors
for genotypes.
A score statistic to test H0 : b1~0 can be computed in closed
form. Due to the complexities involved in computing kernel
weights, the score statistic does not follow a normal distribution.
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significance. When no additional covariates are controlled, the
score function U satisfies U~
P
j Xj Yj{  Y Y
  
[40]. Simple
algebraic manipulations will lead to the equivalence of the score
function U and the KBAC statistic (up to a constant scalar). In
addition, when common variants in the gene are also hypothesized
to play a role in the etiology of the phenotype of interest, their
genotypes can be included as covariates and tested in a similar
manner as for the CMC [20].
Monte Carlo Approximation
Monte Carlo approximation under the null hypothesis.
Although using permutation can provide an exact empirical
distribution under the null hypothesis, it can be computationally
prohibitive for large sample sizes and genome-wide association
studies. A Monte Carlo method was developed which enables fast
computation of p-values efficiently. Under the null hypothesis,
conditioning on the genotype counts, ni fg 1ƒiƒk and the total
number of cases and controls nA,n{nA, the number of cases nA
i
with multi-site genotype Gi follows a binomial distribution
nA
i *Binom ni,
nA
n
  
. Due to the low frequencies for each multi-
site genotype containing rare variants, the nA
i ’s are approximately
independent of each other. Therefore, Monte Carlo simulation
can be carried out as shown in algorithm 1:
Algorithm 1:
Step 1: Simulate a k-vector of independent binomials:
m1,m2,      ,mk ðÞ , with mi *
D Binom ni,
nA
n
  
Step 2: Compute U~
P k
i~1
mi
 
nA{ ni{mi ðÞ
 
n{nA      
K0
i mi=ni ðÞ
   2
Step 3: Repeat step 1 and step 2 N times and record each
KBAC statistic calculated as ~ U U~ U1,      ,UN ðÞ . Through
comparing the KBAC statistic calculated from the original data
with the N KBAC statistic from Monte Carlo simulation, the
empirical p-value is given by ^ p p~ 1
N
P N
i~1
I Ui§KBAC ½  .
Monte Carlo approximation under the alternative
hypothesis: power calculations. In this article power
calculations were carried out empirically; haplotypes were
generated using forward time simulations and case-control status
was assigned via a linear log odds model. Power calculations can
also be carried out using Monte Carlo approximation. Under the
alternative hypothesis of disease-gene associations, it is assumed
that the disease model is known (prevalence and population multi-
site genotype frequencies P~ p1,p2,   ,pk ðÞ etc.) Therefore multi-
site genotype frequencies for cases and controls can be assigned.
The set of frequencies in cases and controls is denoted as
PA~(pA
1 ,pA
2 ,   ,pA
k), PU~(pU
1 ,pU
2 ,   ,pU
k ). Conditioning on the
genotype counts, ni fg 1ƒiƒk and the total number of cases and
controls nA,n{nA, the number of cases nA
i with the multi-site
genotype Gi follows a binomial distribution, i.e.
nA
i *Binom ni,
nApA
i
n{nA ðÞ pU
i znApA
i
  
:
The power calculation under significance level a can be carried
out in the following steps:
Algorithm 2:
Step 0: Generate N1 kz1-vectors n1
1,n1
2,   ,n1
k,n1
0
  
,   ,
n
N1
1 ,n
N1
2 ,   ,n
N1
k ,n
N1
0
  
satisfying multinomial distribution i.e.
ni
1,ni
2,   ,ni
k,ni
0
  
*Multi n;p1,p2,   ,pk,1{
X k
l~1
pl
 !
For each vector n1,n2,   ,nk,n0 ðÞ ~ ni
1,ni
2,   ,ni
k,ni
0
  
,w e
follow step 1 to 4:
Step 1: Obtain an empirical distribution under the null by
following step 1 and 2 in algorithm 1. The vector of U’s obtained
is denoted by ~ U U0 and the 1{a ðÞ
th empirical quantile for ~ U U0 is
denoted by U0
a
Step 2: Simulate a k-vector with independent binomials:
m1,m2,      ,mk ðÞ , with ml*Binom nl, nApA
l
n{nA   
pU
l znApA
l
 !
,
l~1,2,   ,k
Step 3: Compute U~
P k
l~1
ml
 
nA{ nl{ml ðÞ
 
n{nA      
K0
l ml=nl ðÞ
   2
Step 4: Repeat step 2 and step 3 N2 times and record each
KBAC statistic calculated as ~ U UA~ UA
1 ,      ,UA
N2
  
. By com-
paring the KBAC statistic calculated from Monte Carlo simulation
with U0
a, the empirical power conditional on n1,n2,   ,nk,n0 ðÞ
~ ni
1,   ,ni
k,ni
0
  
is given by 1{^ b bi~ 1
N2
P N2
j~1
I UA
j §U0
a
hi
.
Step 5: The estimation of unconditional power is given by
averaging ^ b bi
0
s, i.e. 1{^ b b~ 1
N1
P N1
i~1
1{^ b bi
  
Rare Variant Analysis Methods That Are Compared to the
KBAC
The power of WSS, CMC and RVE were compared to KBAC
in the article. A sketch of each method is provided here. More
detailed descriptions can be found in the cited original reference.
WSS was developed by Madsen and Browning [21]. It was
designed to test for the differences of the number of mutations
between cases and controls. Each mutation was weighted
according to its frequency in controls, and lower frequency
variants will be assigned higher weights. The statistical significance
for the WSS statistic is obtained empirically through permutations.
CMC was developed by Li and Leal [20]. When applied to
testing rare variant associations, multiple rare variants in the gene
region are collapsed and carrier frequencies are compared
between cases and control using Pearson’s Chi-square test. The
RVE [3,4] was first introduced in the analysis of sequence data
from Dallas Heart Study. It compares frequency of carriers of rare
variants that are found exclusively in cases or controls using
Fisher’s exact test.
Generation of Genetic Data
Simulation of demographic model and selections. To
evaluate the performance of KBAC, population genetic data was
generated using forward time simulation [22]. Genetic data from
two populations, AA and EA were generated. The parameters for
demographic changes and selection coefficients were estimated in
Boyko et al [23]. For AA, a simple two-epoch model was used
(Figure S10) while for EA, a six parameter complex bottleneck
model was employed (Figure S11). Purifying selection was also
simulated, with s and 2s being the selective disadvantage of
heterozygous and homozygous new mutations. Scaled fitness effect
c~2Ncurrs (where Ncurr is the current effective population size) is
assumed to follow a gamma distribution, which was shown to be
parsimonious and fit the data well. Details of the choice of
parameters can be found in (Text S1). A mutation rate of
mS~1:8|10{8 per nucleotide per generation is assumed. On
average, the coding region for human gene is 1500 base pairs (bp)
long [41,42], therefore 1500 bps was used in the simulation to
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generated. When generating samples, one pool is randomly chosen
for each replicate. The multi-site genotype of an ‘‘individual’’ is
obtained by pairing two randomly sampled haplotypes.
Generation of genetic data using rare variant SFS. In
order to further evaluate the performance of different methods, we
generate genetic data using SFS estimated from genes in ANGPTL
family (ANGPTL 3,4,5 and 6) from DHS. The SFS of rare variants
was estimated using a method of moments approach (see Text S1
for details). When generating samples, estimated rare variants
frequencies for one ANGPTL gene is randomly picked for each
replicate. The multi-site genotype of an ‘‘individual’’ is generated
according to the chosen set of gene variant frequencies.
Generation of phenotype data with only main
effects. The disease status of each ‘‘individual’’ is assigned
based upon their multi-site genotypes consisting of only those rare
NS variants (MAF#1%). Fifty-percent of the rare NS variant
nucleotide sites were selected to be causal, where the rare mutant
allele has an effect on the disease odds and the remaining rare
variant sites are non-causal with no phenotypic effect. Two types
of penetrance models were evaluated. In the first type of model,
the genetic effects of causal variants are constant (OR=3)
regardless of their allele frequencies. For the second class of
models, the genetic effects are inversely correlated with the MAFs.
Disease odds of individual rare variants varies in the range of
2,20. As a majority of rare variants are of extremely low
frequencies, most of the uncovered rare variants in a case control
sample have ORs between 2 and 4. This is compatible with
surveys for multi-factorial diseases [8]. For both classes of
penetrance specifications, a linear log odds model was applied to
assign the affection status for each individual. Assignment of
disease status continues until a sample of 1000 cases and 1000
controls is obtained for each replicate. To evaluate the effects of
misclassification due to non-causal variants, scenarios were
considered where 20%, 40%, 60%, 80%, and 100% of the non-
causal variants with all of the causal variants were included in the
sample. Additionally to evaluate the effect of misclassification due
to exclusion of causal variants, 20%, 40%, and 60% of the causal
variants were excluded from the analysis, while no non-causal
variants are included in the analysis.
Generation of data with gene interactions. To evaluate
the within gene interaction and between gene interaction models,
1000 cases/1000 controls and 300 cases/300 controls were
generated for each replicate, respectively. For each model, 25% to
100% of the simulated rare variant sites are causal while the
remaining rare variant sites are non-causal. For the within gene
interaction model, one site with a common variant [MAF.20%] is
randomly selected. The disease status of each ‘‘individual’’ is
assigned based upon theirmulti-site genotypeusinga linearlogodds
model. The genetic effects of causal rare variants are modulated by
the alleles at the chosen common variant site. Each causal rare
variant increasesdisease risk with an OR of 3 only if the rare variant
is on the same haplotype as the minor allele from the common
variant site, otherwise the OR=1. For the between gene interaction
model, two unlinked genes are simulated for each ‘‘individual’’. The
disease status of each ‘‘individual’’ is assigned based upon their joint
multi-site genotype at high risk gene 1 and low risk gene 2 using a
linear log odds model. Each causal rare variant in gene 2 increases
disease risk with an OR of 2.0 if there are no causal rare variants in
gene 1; however, if there are rare causal variants in gene 1, the
causalvariants ingene 2 do not increase risk andeachcausalvariant
in gene 1 increases disease risk with an OR of 4.0 regardless of the
genotype at gene 2. Mathematical illustrations of these two models
are shown in Text S1.
Analysis of Energy Metabolism Traits and Rare Variants in
ANGPTL 3, 4, 5 and 6
The DHS dataset is a multi-ethnic population based probability
sample [1830 AA, 601 Hispanics (H), 1045 EA, and 75 from other
ethnicities] from Dallas County residents whose lipids and glucose
metabolism have been characterized and recorded [26,43]. In
order to investigate how sequence variations in ANGTPL3, 4, 5
and 6 influence energy metabolism in humans, coding regions of
the four gene were sequenced using DNA samples obtained from
3551 participants in DHS [5]. A total of 348 nucleotide sites of
sequence variations were uncovered in all four genes. Most of
them are rare and 86% of them have MAFs below 1% [5].
Individuals with diabetes mellitus, heavy alcohol use, or who were
taking lipids lowering drugs were removed from the all the
analyses because these factors could be potential confounders.
Additionally individuals who do not belong to the AA, H or EA
ethnic groups were removed from the analysis. Following the
original study [5], and to control for potential confounders [44] we
stratified the sample by race, sex, and quantitative trait level. For
each quantitative trait, to test if the rare variants are enriched in
the expected extremes, individuals from bottom and top quartiles
are used to mimic a case-control type of design. The KBAC, WSS,
CMC and RVE were applied to carry-out the association analysis.
Supporting Information
Figure S1 Schematic illustration of the permutation procedure
used for evaluating statistical significance empirically.
Found at: doi:10.1371/journal.pgen.1001156.s001 (0.19 MB TIF)
Figure S2 Impact of misclassifications under main effects model
with fixed genetic effects using simulated SFS for EA.
Found at: doi:10.1371/journal.pgen.1001156.s002 (0.18 MB TIF)
Figure S3 Impact of misclassifications under main effects model
with variable genetic effects using simulated SFS for EA.
Found at: doi:10.1371/journal.pgen.1001156.s003 (0.18 MB TIF)
Figure S4 Impact of misclassifications under main effects model
with fixed genetic effects using estimated SFS for AA from genes in
ANGPTL family.
Found at: doi:10.1371/journal.pgen.1001156.s004 (0.18 MB TIF)
Figure S5 Impact of misclassifications under main effects model
with variable genetic effects using estimated SFS for AA from
genes in ANGPTL family.
Found at: doi:10.1371/journal.pgen.1001156.s005 (0.18 MB TIF)
Figure S6 Impact of misclassifications under main effects model
with fixed genetic effects using estimated SFS for EA from genes in
ANGPTL family.
Found at: doi:10.1371/journal.pgen.1001156.s006 (0.18 MB TIF)
Figure S7 Impact of misclassifications under main effects model
with variable genetic effects using estimated SFS for EA from
genes in ANGPTL family.
Found at: doi:10.1371/journal.pgen.1001156.s007 (0.18 MB TIF)
Figure S8 Power comparisons for within gene (left panel) and be-
tween gene interaction model (right panel) with simulated SFS for EA.
Found at: doi:10.1371/journal.pgen.1001156.s008 (0.19 MB TIF)
Figure S9 Graphical Illustrations for KBAC Statistic. In the
KBAC framework, variants adaptive weighting and testing of
associations are simultaneously performed. The statistical signif-
icance can be evaluated using either permutations or Monte Carlo
approximations. For information on nomenclature used please
refer to the Materials and Methods section.
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Figure S10 Demographic History of AA with Two-Epoch
Change.
Found at: doi:10.1371/journal.pgen.1001156.s010 (0.06 MB TIF)
Figure S11 Complex Demographic History of EA.
Found at: doi:10.1371/journal.pgen.1001156.s011 (0.09 MB TIF)
Table S1 Rare variant summary statistics. The summary
statistics are displayed for the generated replicates under main
effects model with fixed and variable genetic effects using
simulated SFS from EA population. Scenarios with different
proportions of causal variants excluded and scenarios with
different proportions of non-causal variants included were
considered. The table displays for a given sample, the information
on a) the average proportion of rare NS variant carriers among
cases and controls; b) the mean number of rare NS variant sites; c)
the mean number of rare NS variant sites that are exclusive to
cases or controls; d) the average proportion of case and control
rare NS variant carriers with more than one rare variant. For each
scenario, a sample size of 1,000 cases and 1,000 controls were
used. 2,000 replicates were generated for each scenario.
Found at: doi:10.1371/journal.pgen.1001156.s012 (0.05 MB
DOC)
Table S2 Rare variant summary statistics. The summary
statistics are displayed for the generated replicates under within
gene interaction model and between gene interaction model using
simulated SFS from EA population. Scenarios with different
proportions of causal variants were considered. The table displays
for a given sample, the information on a) the average proportion of
rare NS variant carriers among cases and controls; b) the mean
number of rare NS variant sites; c) the mean number of rare NS
variant sites that are exclusive to cases or controls; d) the average
proportion of case and control rare NS variant carriers with more
than one rare variant. For within gene interaction model, a sample
size of 1,000 cases and 1,000 controls were used, and for between
gene interaction model, a sample size of 300 cases and 300
controls were used. 2,000 replicates were generated for each
scenario.
Found at: doi:10.1371/journal.pgen.1001156.s013 (0.04 MB
DOC)
Table S3 Rare variant summary statistics. The summary
statistics are displayed for the generated replicates under main
effects model with fixed and variable genetic effects. Estimated
SFS from AA population with ANGPTL dataset was used.
Scenarios with different proportions of causal variants excluded
and scenarios with different proportions of non-causal variants
included were considered. The table displays for a given sample,
the information on a) the average proportion of rare NS variant
carriers among cases and controls; b) the mean number of rare NS
variant sites; c) the mean number of rare NS variant sites that are
exclusive to cases or controls; d) the average proportion of case and
control rare NS variant carriers with more than one rare variant.
For each scenario, a sample size of 1,000 cases and 1,000 controls
were used. 2,000 replicates were generated for each scenario.
Found at: doi:10.1371/journal.pgen.1001156.s014 (0.04 MB
DOC)
Table S4 Rare variant summary statistics. The summary
statistics are displayed for the generated replicates under main
effects model with fixed and variable genetic effects. Estimated
SFS from EA population with ANGPTL dataset was used.
Scenarios with different proportions of causal variants excluded
and scenarios with different proportions of non-causal variants
included were considered. The table displays for a given sample,
the information on a) the average proportion of rare NS variant
carriers among cases and controls; b) the mean number of rare NS
variant sites; c) the mean number of rare NS variant sites that are
exclusive to cases or controls; d) the average proportion of case and
control rare NS variant carriers with more than one rare variant.
For each scenario, a sample size of 1,000 cases and 1,000 controls
were used. 2,000 replicates were generated for each scenario.
Found at: doi:10.1371/journal.pgen.1001156.s015 (0.04 MB
DOC)
Text S1 Supplementary Material.
Found at: doi:10.1371/journal.pgen.1001156.s016 (0.25 MB
DOC)
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